AcnePodcast Highlights

Systemic Antibiotics in the Management of Acne: Issues and Considerations for Optimal Care

By August 7, 2020September 7th, 2020No Comments

JDD Multimedia

JDD Podcast

Listen Now

How to Listen

"Systemic Antibiotics in the Management of Acne: Issues and Considerations for Optimal Care"

Drs. Joslyn Kirby and Adam Friedman

 

WEEEEEEERE BACK! Join host Dr. Adam Friedman for lively and learned discussion with Dr. Joslyn Kirby on one of the most common, chronic, soul-crushing complaints… Acne Vulgaris. It is, from a pathophysiological standpoint, a biological sh*t show, but you need to understand it to develop the best treatment plans. We talk inflammation, first line approaches, setting patient expectations and compliance. We dive deep into the differences between broad-spectrum and narrow-spectrum antibiotics, when to use them, and for how long. (Spoiler alert: NOT TOO LONG!). In our efforts to be stewards of meaningful antibiotic use and adversaries of antimicrobial resistance, narrow-spectrum antibiotics are the future!

This enduring activity is supported by an independent medical education grant provided by Almirall, LLC.

Upon completion of this enduring, internet-based educational activity, participants should be able to:

  • Review current scientific understanding of pathophysiology of acne
  • Summarize acne treatment strategies utilizing systemic antibiotics
  • Differentiate safety and efficacy of broad and narrow spectrum antibiotics indicated for acne treatment
  • Cite the benefits of narrow spectrum antibiotic use in acne therapy
Listen Now
Disclosures:
  • Adam Friedman, MD, FAAD – Grant/Research: Aclaris, CPN, Almirall. Consultant: SanovaWorks, Oakstone Institute, L’oreal, La Roche Posay, Galderma, Aveeno, Valeant, Microcures, Biogen, Pfizer, G&W Laboratories, Novartis, Occulus, Intraderm, Encore, Exeltis, Menlo, Lilly, Aclaris, Dermira, Berg, Allergan, Zylo Therapeutics, Hoth. Speaker’s Bureau: Regeneron, Dermira, Janssen, AbbVie. Major Stock Shareholder: Zylo, Minorcures.
  • Joslyn R. Sciacca Kirby, MD – No relevant disclosures.

You May Also Like

Data Driven Dealings for Disabling Dysfunctional Diabetic (epi)Dermal Disorders

| Dermatology Podcast Archives, Featured Podcast, JDD Highlights, Podcast Highlights | No Comments
iTunes Google Play Stitcher TuneIn Spotify Dr. Robert Kirsner & Adam Friedman, MD, FAAD Sometimes the most common and obvious problems fall through the cracks. Focusing in a bit, the…

Protect Ya Neck: Ensuring Accessible Education and Care for Patients with Acne Keloidalis Nuchae

| Acne, Dermatology Podcast Archives, Featured Podcast, JDD Highlights, Podcast Highlights | No Comments
j iTunes Google Play Stitcher TuneIn Spotify Dr. Nanette Silverberg & Adam Friedman, MD, FAAD There are a number of dermatologic conditions that in part result from our daily behaviors -…

Plant(ing) Evidence: An overview of the oral nutraceutical landscape and innovative vehicles to enhance their impact

| Dermatology Podcast Archives, Featured Podcast, Podcast Highlights | No Comments
j iTunes Google Play Stitcher TuneIn Spotify Giorgio Dell’Acqua, PhD & Adam Friedman, MD, FAAD The over the counter nutraceutical landscape can be overwhelming, daunting, and costly – at a…

Leave a Reply